Proyecto
 (2014)

A Phase 3 Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Doravirine (MK-1439) 100 mg Once Daily Versus Darunavir 800 mg Once Daily Plus Ritonavir 100 mg Once Daily, Each in Combination With TRUVADA™ or EPZICOM™/KIVEXA™, in Treatment-Naïve HIV-1 Infected Subjects

Merck Sharp & Dohme LLC

Más información

Fecha de publicación: 2014
Objetivos: Primary Outcome Measures: Percentage of Participants Achieving Plasma HIV-1 RNA <50 Copies/mL at Week 48.
Año de Inicio/Término: 2014-2023
Financiamiento/Sponsor: Merck Sharp & Dohme LLC
Rol del Usuario: COLABORADOR(A)
URL: https://clinicaltrials.gov/ct2/show/NCT02275780
DOI:

1439-018